Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial
Erstveröffentlichung
2009
Wissenschaftlicher Artikel
Erschienen in
Blood ; 114 (2009), 13. - S. 2589-2597. - ISSN 0006-4971
Link zur Veröffentlichung
https://dx.doi.org/10.1182/blood-2009-05-224071Institutionen
UKU. Klinik für Innere Medizin IIISchlagwörter
[Freie Schlagwörter]: joining dna-repair | phase-3 trial | plus cyclophosphamide | cytogenetic analysis | genomic aberrations | 1st-line therapy | drug-resistance | cd38 expression | gene-expression | b-cells[DDC Sachgruppe]: DDC 610 / Medicine & health